Mineralys Therapeutics, Inc. MLYS
15.81 USD +0.48 (+3.13%)
At closeNov 9, 2026, 6:50 PM EST
15.90 +0.09 +0.57%
After hours · Nov 9, 6:50 PM ET
15.20 Day range 16.40
14.91 52-week range 47.65
- YTD
- -56.43%
- 1 year
- -58.42%
News
seekingalpha.com Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade) Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited differentiation from BAXFENDY on efficacy or safety. MLYS faces AstraZeneca's entrenched cardiorenal franchise,…
marketbeat.com What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call Mineralys Therapeutics NASDAQ: MLYS is preparing to launch its hypertension drug candidate lorundrostat if it wins regulatory approval, with a U.S. Food and Drug Administration decision targeted for…
seekingalpha.com Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript
benzinga.com Mineralys Therapeutics Q3 2026 Earnings Call Transcript Mineralys Therapeutics (NASDAQ:MLYS) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
globenewswire.com Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled…
globenewswire.com Mineralys Therapeutics to Participate in Upcoming Investor Conferences RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
benzinga.com Mineralys Therapeutics Announces Phase 2 Explore-CKD Trial Met Its Primary Endpoint; Publishes Full Results In The Journal 'Kidney International' The Explore-CKD trial evaluated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, added to guideline-directed background therapy in 59 participants with uncontrolled…
benzinga.com UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29 UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.
benzinga.com HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.
benzinga.com Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic…
benzinga.com Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026, Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as…- benzinga.com Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026 Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as…
benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Significant Reductions In Six Of Eleven Heart Failure Risk Biomarkers – Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –– Coordinated reductions…
- benzinga.com Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO Poster Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
benzinga.com AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breast cancer treatment.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Mineralys Therapeutics Q1 EPS $(0.47), Inline Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from…
benzinga.com B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51 B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.- benzinga.com Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.58) by 30.68 percent. This is a 59.18 percent increase over losses…
- benzinga.com Earnings Scheduled For March 12, 2026
benzinga.com Mineralys Therapeutics Says FDA Accepts NDA For Lorundrostat For Treatment Of Adult Patients With Hypertension In Combination With Other Antihypertensive Drugs; PDUFA Target Action Date December 22 – The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction…- benzinga.com Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52 Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
- benzinga.com Mineralys Therapeutics' Phase 3 Launch-HTN Trial Of Lorundrostat Featured In JAMA's Inaugural "Research Of The Year Roundup" – Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most…
- benzinga.com HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56 HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
- benzinga.com Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55 Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
- benzinga.com Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.65) by 19.38 percent. This is a 53.98 percent increase over losses…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Cardio-Renal-Metabolic Diseases – Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN trial featured in the "Best of JAMA and NEJM" session -
benzinga.com Uncovering Potential: Mineralys Therapeutics's Earnings Preview - benzinga.com HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52 HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
- benzinga.com Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025 ~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN…
- benzinga.com Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $50 Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $26 to $50.
- benzinga.com Goldman Sachs Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52 Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $32 to $52.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $42 price target.
- benzinga.com Mineralys Therapeutics Presents Subgroup Data From Phase 3 Launch-HTN Trial At AHA 2025, Highlighting Lorundrostat's Efficacy In High-Risk Hypertension Populations ~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~~Subgroups - including Black or…
benzinga.com Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com Jefferies Maintains Hold on Mineralys Therapeutics, Raises Price Target to $26 Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $15 to $26.
benzinga.com Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Nasdaq Down 1%; Signet Jewelers Earnings Top Views - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket 
benzinga.com Nasdaq 100, S&P 500 Hit New All-Time Highs, Airlines Jump: What's Moving Markets Tuesday? Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost pressures were widespread. The headline Consumer Price Index (CPI) came in below expectations,…- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Earnings Scheduled For May 12, 2025
benzinga.com Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session